Evidence map›Paper›PMID 40782219›Full record

ArticleJournal of endocrinological investigation2025

MASLD-related fibrosis, but not MASLD, is associated with left ventricular concentric hypertrophy in patients with type 2 diabetes.

Jiayang Lin, Ruxin Chen, Junlin Huang, Yating Liu, Chensihan Huang, Yan Huang, Bingyan Xu, Yunqian Li, Xinyu He, Hongzhen Lv and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jiayang Lin *Department of Endocrinology and metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Ruxin Chen *Department of Endocrinology and metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Junlin Huang *Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.
Yating LiuDepartment of General Medicine, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
Chensihan HuangDepartment of Endocrinology and metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yan HuangDepartment of Endocrinology and metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Bingyan XuDepartment of Endocrinology and metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yunqian LiDepartment of Endocrinology and metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Xinyu HeDepartment of Endocrinology and metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Hongzhen LvDepartment of Endocrinology and metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Xueyun WeiDepartment of Endocrinology and metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Peizhen ZhangDepartment of Endocrinology and metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Dan GuoDepartment of Endocrinology and metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Jinhua ZhangKey Laboratory of Functional and Clinical Translational Medicine, Department of General Medicine, Xiamen Medical College, Xiamen, China.
Huijie ZhangDepartment of Endocrinology and metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, China. huijiezhang2005@126.com.ORCID http://orcid.org/0000-0003-0640-0315

Funding

Dean's Fund of Nanfang Hospital, Southern Medical University No.2023B044Joint Funds of the National Natural Science Foundation of China U22A20288Key-Area Clinical Research Program of Southern Medical University Nos.LC2019ZD010 and 2019CR022National Key Research and Development Project No.2018YFA0800404National Natural Science Foundation of China No.82400986National Science Fund for Distinguished Young Scholars No.82325011Noncommunicable Chronic Diseases-National Science and Technology Major Project of China No.2023ZD0508300
6 · The paper itself

Abstract

purposeTo assess the association of metabolic dysfunction-associated steatotic liver disease (MASLD) and related fibrosis with abnormal left ventricular (LV) geometry in patients with type 2 diabetes mellitus (T2DM).

methodsThis cross-sectional study included 1026 participants with T2DM in Nanfang Metabolic Study who underwent FibroScan and echocardiography. MASLD and liver fibrosis was assessed by FibroScan with controlled attenuation parameter (CAP) and liver stiffness measurement (LSM), which quantifies liver steatosis and fibrosis, respectively. LV geometry was evaluated by echocardiography, with patterns classified as: normal geometry, concentric remodeling, eccentric hypertrophy, and concentric hypertrophy. The association of MASLD and related fibrosis with risks of abnormal LV geometry patterns was assessed by multivariate logistic regression models, adjusted for 27 biomarkers detected by directed acyclic graph.

resultsParticipants had a mean age of 51.2 years, mean BMI of 25.0 kg/m2, and 633 (62%) were male. 579 (56%) of the participants had MASLD (CAP > 248 dB/m), 118 (12%) of whom had significant liver fibrosis (LSM > 7 kPa). Multivariate logistic regression analysis revealed that MASLD-related fibrosis, but not MASLD itself, was independently associated with LV concentric hypertrophy (odds ratio, 1.89; 95% confidence interval, 1.23 to 2.91; p = 0.004). Neither MASLD nor its related fibrosis was significantly associated with other abnormal LV geometry patterns.

conclusionsOur findings indicated that MASLD-related fibrosis was independently associated with LV concentric hypertrophy in patients with T2DM.

Indexed as

Diabetes Mellitus, Type 2Hypertrophy, Left VentricularLiver CirrhosisNon-alcoholic Fatty Liver DiseaseCross-Sectional StudiesEchocardiographyFemaleFibrosisFollow-Up StudiesHumansMaleMiddle AgedPrognosisConcentric hypertrophyFibroScanLeft ventricular geometryLiver fibrosisMASLDT2DM

Identifiers

PMID40782219

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.